Original articleModulation of transglutaminase activity in mononuclear phagocytes and macrophage-like tumor cell lines by differentiation agents☆
References (34)
- et al.
J biol chem
(1983) - et al.
Biochem biophys res commun
(1982) - et al.
J biol chem
(1985) - et al.
Mol immunol
(1981) - et al.
Exp cell res
(1982) - et al.
J biol chem
(1984) - et al.
Blood
(1981) Anal biochem
(1976)- et al.
J biol chem
(1983) - et al.
J biol chem
(1983)
Exp cell res
(1982)
Biochim biophys acta
(1980)
Ann NY acad sci
(1978)
Annu rev biochem
(1980)
J exp med
(1984)
Eur j immunol
(1981)
J natl cancer inst
(1983)
Cited by (10)
The synergistic role of Pu.1 and Fms in zebrafish osteoclast-reducing osteopetrosis and possible therapeutic strategies
2020, Journal of Genetics and GenomicsCitation Excerpt :Thus, these osteopetrosis animal models may provide chances for therapeutic osteopetrosis drug development. RA, a commonly used clinical drug for acute promyelocytic leukemia (Huang et al., 1988), has been reported to promote osteoclast proliferation and differentiation (Goldman, 1987; Kaji et al., 1995; Jeradi and Hammerschmidt, 2016). Thus, we wanted to know whether RA could activate osteoclasts and rescue osteopetrosis in pu.1G242D and fmsj4e1 zebrafish models.
Human mononuclear phagocyte transglutaminase activity cross-links fibrin
1989, Thrombosis ResearchImproved maintenance of adult rat alveolar type II cell differentiation in vitro: effect of hydrocortisone and cyclic AMP
1988, BBA - Molecular Cell ResearchTransamidating activities of factor XIII<inf>a</inf> and of transglutaminases, measured by an Elisa procedure
1988, Biochemical and Biophysical Research Communications
- ☆
The work was supported in part by the Edward D. and Anna Mitchell Research Fund.
Copyright © 1987 Published by Elsevier Inc.